Search results: (10000)
News Sustained Remission of ITP with Thrombopoietin Receptor Agonists Treatment
Thrombopoietin receptor agonists (TPO-RAs) are highly effective drugs administered in chronic immune thrombocytopenia (ITP). Several studies have shown that they can induce remission and long-term response, even after prolonged discontinuation.
News Over 10 Years of Experience with TPO-RA in the Treatment of Immune Thrombocytopenia
Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an integral part of the therapy for patients with immune thrombocytopenia (ITP) over the past more than 10 years. Their administration represents a new approach compared to the previous, long-established treatment, and has significantly changed the prognosis of the disease in many patients.
News How can inosine pranobex help with viral infections?
Inosine pranobex has long been used for its immunomodulatory and antiviral effects in the prophylaxis and therapy of various viral infections. Below we summarize its mechanism of action, indications, usage, and side effects.
News Register of Patients Treated with Growth Hormone (REPAR): Data Analysis as a Path to Further Optimization of Care
Treatment with recombinant growth hormone (rhGH) is available in the Czech Republic for all children meeting the indication criteria. A network of 10 centers covers the entire country, and all doctors authorized to prescribe growth hormone are united in the Pediatric Growth Hormone Working Group. The Czech national Register of Patients Treated with Growth Hormone (REPAR) has been collecting data on patients treated with rhGH since 2014. The aim of the presented work was to analyze selected data and present the basic demographics of patients included in this database during the first 5 years of its existence.
News Targeted Treatment of HER2-Positive Breast Tumors – Updates from ESMO 2020 Congress
The recent European Society for Medical Oncology (ESMO) Congress took place virtually. We bring you a brief summary of the presentations related to the treatment of HER2-positive breast tumors.
News Romiplostim in Life-Threatening Bleeding Situations − Case Reports
Immune thrombocytopenic purpura, or immune thrombocytopenia (ITP), typically manifests as bleeding due to a low platelet count. Some bleeding episodes can be life-threatening or fatal. Clinical experience suggests that in acute bleeding complications, whether in acute ITP or exacerbations of chronic ITP, early use of the thrombopoietin receptor agonist (TPO-RA) romiplostim can be beneficial. Japanese authors have described three case reports of severe diffuse alveolar hemorrhage (DAH) associated with various underlying conditions.
News Development of Albuminuria During Treatment with ACE Inhibitors and Sartans
Individual molecules from the class of renin-angiotensin system inhibitors display various distinct properties at the molecular level, and their renoprotective potential may differ. A study by Korean authors observed the development of renal parameters in individuals with albuminuria during the first 3 months after the initiation of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), also known as sartans.
News IEC 2023: Key Challenges for Epilepsy Patients Include Status Epilepticus and Anxiety Management
Why is anxiety a significant issue for epilepsy patients? What do current insights say about the connection between epilepsy and anxiety? Can artificial intelligence be used to predict status epilepticus (SE)? And what is known about the development of late epilepsy following new SE? These and other topics were discussed in September 2023 in Dublin during the 35th International Epilepsy Congress (IEC 2023).
News Profile of the effect of aclidinium bromide compared to glycopyrronium bromide
A study by Spanish authors examined the profiles of 2 long-acting muscarinic receptor antagonists (LAMA), aclidinium bromide and glycopyrronium bromide, under in vitro and in vivo conditions.
News Subcutaneous Immunoglobulin Substitution in Ig-Naive Patients with PID – Available Efficacy and Safety Data
The prevalence of primary immunodeficiencies (PID) is estimated at 1:10,000. Below, we summarize the available findings on the efficacy and safety of subcutaneous immunoglobulin substitution in Ig-naive patients (i.e., without prior immunoglobulin substitution).
News Is it possible to extend the life of diabetics thanks to modern treatment?
People aged 60 with type 2 diabetes are estimated to live on average 6-7 years less compared to their peers without a diabetes diagnosis. However, clinical study results suggest that modern therapy can prevent these lost years.
News “Think about the thyroid gland during pregnancy,” reminds awareness campaign
Thyroid disorders can endanger the health of both the fetus and the mother. Sometimes, however, the problem only manifests during pregnancy, and the expectant mother or her doctor might not notice it amidst other ongoing changes. The issue was highlighted by an event called “Thyroid Week,” which took place in the Czech Republic during the last week of May 2020.
News Excellent effect of sotorasib in a higher line of treatment in a patient with NSCLC with G12C mutation of KRAS – a case study
We present a case study of an elderly patient with non-small cell lung cancer (NSCLC) treated with the selective KRASG12C inhibitor sotorasib in the 5th line of oncological treatment, but with a very exceptional effect.
News Impact of Early Administration of High Protein Dose on Mortality of Critically Ill Patients
Energy intake and the composition of individual macronutrients in patients in intensive care units (ICUs) can influence treatment outcomes in terms of the incidence of complications, duration of mechanical ventilation, or mortality.
News With Prof. Pavel Žák about Current Trends and Future Perspectives in Bone Marrow Transplantation and the Role of Carmustine in this Context
Hematopoietic stem cell transplantation has an indispensable place in the treatment of hemato-oncological diseases. We discuss current trends in this area, the significance and benefits of carmustine, the choice between BEAM and TEAM regimens, and the future of bone marrow transplantation in the context of new technologies with the head of the 4th Department of Hematology of the Faculty of Medicine, Charles University and University Hospital Hradec Králové, Prof. MUDr. Pavel Žák, Ph.D.
News Deficit Alpha-1-Antitrypsin as an Underestimated Problem? What a Survey Among European Experts Revealed
Alpha-1-antitrypsin deficiency (AATD) is a congenital disorder caused by mutations in the SERPINA1 gene. Although it is very well described, it is considered underdiagnosed and undertreated. A recent international survey conducted among specialists on this issue aimed to determine the current situation in Europe.
News Comparison of BEAM and TEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Lymphomas
At the beginning of this year, one of the few studies comparing the most commonly used conditioning regimen before autologous hematopoietic stem cell transplantation (ASCT) in patients with lymphomas (BEAM) with a regimen containing thiotepa instead of carmustine (TEAM) was published.
News Brentuximab Vedotin and Relapsing/Refractory NHL with High Expression of CD30
A recently published study by authors from South Korea focused on examining the efficacy of brentuximab vedotin in patients with non-Hodgkin lymphomas (NHL) that highly express CD30 (i.e., > 30% CD30-positive tumor cells based on immunohistochemistry), where the disease had relapsed or was refractory to previous treatments.
News Meta-analysis of the efficacy and safety of dupilumab in the treatment of atopic dermatitis in children and adults
Moderate to severe atopic dermatitis (AD) is accompanied by strong inflammatory processes that can occur anywhere on the skin, intense itching, and pain. The biologic dupilumab is a promising molecule for the treatment of severe forms of this condition – results from a recently published meta-analysis indicate that this therapy is not only effective but also well-tolerated by patients.
News Prognostic Model MSKCC in Patients with Metastatic Renal Carcinoma Treated in 1st Line with Sunitinib
A study by Czech authors published in 2020 demonstrated the usefulness of the MSKCC (Memorial Sloan Kettering Cancer Center) model in the prognostic stratification of patients with metastatic renal carcinoma (mRCC) treated with sunitinib in the 1st line. Additionally, a significant difference was found between the outcomes achieved in patients with intermediate risk who had one or two risk factors.
News How to Dose Beta-Blockers After Myocardial Infarction?
In patients after myocardial infarction (MI), there is a frequent administration of too low doses of beta-blockers (BB) and rare upward titration of their dose after discharge from the hospital. The SWEDEHEART study investigated to what extent the BB dose actually affects 5-year cardiovascular (CV) outcomes, and data from the American registry allowed a focus on mortality after MI depending on BB dosing.
News Immunomodulation and Romiplostim − What Does the Recently Published iROM Study Say?
Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only the production of antibodies but also changes in cytokine levels, predominance of Th1 lymphocytes over Th2, increase in Th17 cells, and conversely a decrease in T-regulatory lymphocytes (Tregs). One treatment option is the use of thrombopoietin receptor agonists (TPO-RA), which primarily increase platelet production. Recently, attention has also been focused on their potential immunomodulatory effects and protolerogenic effect associated with Tregs activation, which was the subject of the Swiss iROM study.